Mydecine to Report Full Year 2020 Financial Results on May 3, 2021

DENVER, April 26, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced today that it will report its financial results for the full year ended December 31, 2020, before the market open on Monday, May 3, 2021.

The Company will host a conference call and audio webcast that morning at 10:30 a.m. ET featuring remarks by Josh Bartch, CEO and Dean Ditto, CFO.

Event:	Mydecine Full Year 2020 Financial Results Conference Call
Date:	Monday, May 3, 2021
Time:	10:30 a.m. Eastern Time
Live Call:	1-877-407-4018 (U.S. Toll Free) or 1-201-689-8471 (International)
Webcast:	http://public.viavid.com/index.php?id=144246

For interested individuals unable to join the conference call, a replay of the call will be available through May 17, 2021, at [phone] (U.S. Toll Free) or [phone] (International). Participants must use the following code to access the replay of the call: 13718466. The online archive of the webcast will be available on https://www.mydecine.com/#investors after the conclusion of the call.

About Mydecine Innovations Group
Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.